Healthcare Industry News: ViewFlex
News Release - December 18, 2006
EP MedSystems Advances the Integration of Electrophysiology Lab Equipment with Launch of MapMate(TM) InterfaceWEST BERLIN, N.J.--(HSMN NewsFeed)--EP MedSystems, Inc. (NASDAQ: EPMD ), today announced the launch of its MapMate(TM) Interface link between its EP-WorkMateŽ Recording System and CARTOŽ XP Navigation and Ablation System. The CARTO XP System, from Biosense Webster, is the leading 3D navigation system used in advanced ablation procedures for treatment of patients with irregular heartbeats. The MapMate interface was recently cleared by the FDA for marketing and distribution in the United States.
The MapMate Interface between EP-WorkMate and CARTO XP System was designed to simplify procedures by having the recording system and the three dimensional navigation system communicate with each other to combine diagnostic data from each system and eliminate duplicate demographic data entry.
David Bruce, President and CEO of EP MedSystems commented: "We are pleased to launch our MapMate Interface, another new product focused on integrating and streamlining workflow between the various systems used in Electrophysiology procedures. It's available for new WorkMate system installations and as an upgrade to our installed base of WorkMate systems. As a clinical tool it helps simplify procedures, and as a business opportunity it can increase our average system revenue and offers upgrade revenue from our installed base."
Dr. Koonlawee Nadamanee, MD, FACC, FAHA, Director, Pacific Rim Electrophysiology Research Institute, stated," The MapMate interface fulfills the need for better integration and communication between the numerous systems in the EP lab. Being able to interface electrogram and 3D electroanatomical data creates workflow efficiencies and is an invaluable tool during my complex ablations letting me better focus on the patient and his outcome."
Currently most labs must separately enter and manage patient data on their individual recording and navigation systems. By linking the detailed electrograms from sites within the heart to the 'roadmap' used in conducting ablation procedures, MapMate Interface allows clinicians to rapidly see complete information to conduct the proper course of treatment, and produce comprehensive case reports from the EP-WorkMate Recording System.
About EP MedSystems:
EP MedSystems develops and markets cardiac electrophysiology ("EP") products used in imaging, diagnosing and treating certain cardiac rhythm disorders. The Company's EP product line includes the EP-WorkMateŽ Electrophysiology Workstation, the EP-4(TM)Computerized Cardiac Stimulator, fixed and deflectable diagnostic electrophysiology catheters and related disposable supplies, the NurseMate(TM) Remote Review Station, and the ViewMateŽ intracardiac ultrasound catheter imaging and ViewFlex(TM) Intracardiac Ultrasound Catheter. For more information, visit our Website at www.epmedsystems.com.
Forward Looking Statements:
This Release may contain certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Forward-looking statements include information concerning our possible or assumed future results of operations and statements preceded by, followed by or including the words "believes", "expects", "anticipates", "intends", "plans", "estimates", "see opportunities" or similar expressions. Such forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, EP MedSystems' history of losses, uncertainty of market acceptance of our products and level of sales, uncertainty of future profitability and future liquidity needs, possible costs, fines or penalties that may be incurred in connection with government inquiries and investigations and risks regarding regulatory approvals and demand for new and existing products, as stated in the Company's Annual Report filed on Form 10-K and quarterly reports filed on Form 10-Q.
EP MedSystems cautions investors and others to review the cautionary statements set forth in this press release and in EP MedSystems' reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the EP MedSystems' business and results of operations. Readers are cautioned not to place undue reliance on this press release and other forward-looking statements, which speak only as of the date of this release. EP MedSystems undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.
Source: EP MedSystems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.